Testing a digital monitoring tool for people who stopped chronic myeloid leukemia treatment
Tests whether a digital tool can support follow-up after stopping chronic myeloid leukemia treatment.
Plain-language title generated from the registry record
Registry title: Feasibility Study to Evaluate a Digital Tool for Monitoring Patients Who Have Discontinued Treatment for Chronic Myeloid Leukemia
Key facts
- Where
- Le Chesnay, FranceSee the site
Where in France
- CH de VersaillesLe Chesnay, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Versailles Hospital
- Trial code
- NCT07760311
- Record updated
- 12 August 2026
- Original description
The objective of this project is to evaluate, over a 12-month period, the feasibility of integrating a digital tool into the follow-up care of patients with chronic myeloid leukemia who have been off treatment for up to 2 years. Feasibility will be assessed based on the usage rate, defined as the proportion of patients who accessed the digital tool at least:Read full original descriptionShow less
Feasibility Study to Evaluate a Digital Tool for Monitoring Patients Who Have Discontinued Treatment for Chronic Myeloid Leukemia
The objective of this project is to evaluate, over a 12-month period, the feasibility of integrating a digital tool into the follow-up care of patients with chronic myeloid leukemia who have been off treatment for up to 2 years. Feasibility will be assessed based on the usage rate, defined as the proportion of patients who accessed the digital tool at least:
* once a month, if treatment discontinuation was ≤ 6 months; * once a quarter, if treatment discontinuation was > 6 months. The usage rate will be assessed and compared to a threshold of 60%; if the rate falls below this threshold, feasibility will be considered insufficient.
Inclusion: Patients aged 18 or older; Patients with chronic myeloid leukemia who have been off treatment for ≤ 2 years; Patients with access to a digital device with internet access; Be enrolled in the social security system; Have given verbal consent after reviewing the study information sheet.
Exclusion: Patients who cannot read or understand French; Individuals entitled to enhanced protection, namely minors, individuals deprived of their liberty by a judicial or administrative decision, individuals staying in a health or social care facility, adults under legal guardianship, and, finally, patients in emergency situations.